As of close of business last night, Esperion Therapeutics Inc.’s stock clocked out at $2.07, up 0.98% from its previous closing price of $2.05. In other words, the price has increased by $+0.0200 from its previous closing price. On the day, 10729140 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
To gain a deeper understanding of ESPR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.87 and its Current Ratio is at 1.29.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 20 ’23 when Warren Eric sold 742 shares for $1.25 per share. The transaction valued at 924 led to the insider holds 68,318 shares of the business.
Warren Eric sold 243 shares of ESPR for $344 on Aug 18 ’23. The Chief Commercial Officer now owns 69,060 shares after completing the transaction at $1.41 per share. On Jul 19 ’23, another insider, Warren Eric, who serves as the Chief Commercial Officer of the company, sold 106 shares for $1.58 each. As a result, the insider received 168 and left with 69,303 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 383.98M and an Enterprise Value of 567.91M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.03. Its current Enterprise Value per Revenue stands at 4.88 whereas that against EBITDA is -3.78.
Stock Price History:
Over the past 52 weeks, ESPR has reached a high of $4.05, while it has fallen to a 52-week low of $0.70. The 50-Day Moving Average of the stock is 2.4334, while the 200-Day Moving Average is calculated to be 1.6482.
Shares Statistics:
It appears that ESPR traded 6.00M shares on average per day over the past three months and 3.96M shares per day over the past ten days. A total of 170.42M shares are outstanding, with a floating share count of 169.51M. Insiders hold about 0.53% of the company’s shares, while institutions hold 48.10% stake in the company. Shares short for ESPR as of Feb 29, 2024 were 16.95M with a Short Ratio of 2.82, compared to 20.07M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.16% and a Short% of Float of 10.23%.
Earnings Estimates
As of right now, 7 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0.01 for the current quarter, with a high estimate of $0.46 and a low estimate of -$0.31, while EPS last year was -$0.79. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.15 and low estimates of -$0.25.
Analysts are recommending an EPS of between $0.04 and -$1 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is $0.2, with 5 analysts recommending between $1.49 and -$0.34.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $76.86M. It ranges from a high estimate of $141.69M to a low estimate of $28.9M. As of the current estimate, Esperion Therapeutics Inc.’s year-ago sales were $24.33M, an estimated increase of 215.90% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $41.91M, an increase of 62.50% less than the figure of $215.90% in the same quarter last year. There is a high estimate of $48.35M for the next quarter, whereas the lowest estimate is $38M.
A total of 7 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $337.5M, while the lowest revenue estimate was $174M, resulting in an average revenue estimate of $257.54M. In the same quarter a year ago, actual revenue was $116.33M, up 121.40% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $398.87M in the next fiscal year. The high estimate is $710.2M and the low estimate is $272.94M. The average revenue growth estimate for next year is up 54.90% from the average revenue estimate for this year.
